Cimetidine for mucosal warts in an HIV positive adult

Australasian Journal of Dermatology

Volumn 37, Issue 3, 1996, Pages 149-150

  Wargon, Orli ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b NONE   (Australia)

Author keywords

Antihistamines; Histamine H2 antagonists; Human papillomavirus; Immunosuppression

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; AIDS RELATED COMPLEX; ANUS DISEASE; ARTICLE; CASE REPORT; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MALE; MOUTH DISEASE; ORAL DRUG ADMINISTRATION; VERRUCA VULGARIS;

ADMINISTRATION, ORAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANUS DISEASES; CIMETIDINE; FOLLOW-UP STUDIES; HISTAMINE H2 ANTAGONISTS; HIV SEROPOSITIVITY; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MOUTH DISEASES; WARTS;

EID: 0030210729     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-0960.1996.tb01035.x     Document Type: Article

References (17)

1. Choi YS, Hann SK, Park YK. The effect of cimetidine on verruca plana juvenalis: Clinical trials in six patients. J. Dermatol. 1993; 20: 497-500.
2. Orlow SJ, Paller A. Cimetidine therapy for multiple viral warts in children. J. Am. Acad. Dermatol. 1993; 28: 794-6.
3. Kurzrock R, Auber M, Mavligit GM. Cimetidine therapy for herpes simplex virus infections in immunocompromised patients. Clin. Exp. Dermatol. 1987; 12: 326-31.
4. Rocklin RE. Modulation of cellular immune responses in vitro and in vivo by histamine receptor bearing lymphocytes. J. Clin. Invest. 1976; 57: 1051-9.
5. Rocklin RE. Histamine induced suppressor factor: Effect on migration inhibition factor production and proliferation. J. Immunol. 1977; 118: 1734-8.
6. Shearer GM, Melmon KL, Weinstein Y, Sela M. Regulation of antibody response by cells expressing histamine receptors. J. Exp. Med. 1972; 136: 1302-7.
7. Hayne ST, Mercer JB. Herpes zoster: Treatment with cimetidine. Can. Med. Assoc. J. 1963; 129: 1284-5.
8. Nair MPV, Schwartz SA. Effect of histamine and histamine antagonists on natural and antibody dependent cellular cytotoxicity of human lymphocytes in vitro. Cell Immunol. 1983; 81: 45-60.
9. Grekas D, Nakos V, Theocharides A, Spanos P, Arvanitakis C, Tourkantonis A. Prophylactic treatment with cimetidine after renal transplantation. Nephron 1985; 40: 213-15.
10. Brockmeyer NH, Kreuzfelder K, Merlins L, Chalabi N et al. Immunomodulatory properties of cimetidine in ARC patients. Clin. Immunol. Immunopathol. 1988; 48: 50-60.
11. Talpaz M, Medina JE, Patt YZ et al. The immune restorative effect of cimetidine administration in vivo on the local graft-versus-host reaction of cancer patients. Clin. Immunol. Immunopathol. 1982; 24: 155-60.
12. Mauhinney J, Killen M, Flemming WA et al. The hyper IgE syndrome: A neutrophil chemotactic defect reversible by H2 receptor blockade. Clin. Immunol. Immunopathol. 1980; 17: 483-91.
13. Morgan G, Hendrickse W, Harvey BAM et al. Treatment of the hyper IgE syndrome with cimetidine. In: Vossen J, Grisselli (pds). Progress in Immunodeficiency Research and Therapy II. Amsterdam: Elsevier, 1986: 217-20.
14. Neilsen HJ, Neilsen H, Georgensen J. Ranitidine for improvement of treatment-resistant psoriasis. Arch. Dermatol. 1991; 127: 270.
15. Stashower ME, Yeager JK, Smith KJ, Skelton HG, Wagner KF. Cimetidine as therapy for treatment resistant psoriasis in a patient with acquired immunodeficiency syndrome. Arch. Dermatol. 1993; 129: 848-50.
16. Hay RJ, Champion RH, Greaves MW. Systemic therapy. In: Champion RH, Burton JL, Ebling FJG (eds). Textbook of Dermatology, 5th edn. Oxford: Blackwell Science, 1992: 2932.
17. Shinn AF. Clinical relevance of cimetidine drug interactions. Drug Safety 1992; 7: 245-67.